Clinical significance of the serum crosslinked N-telopeptide of type i collagen as a prognostic marker for non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 1, 2013, Pages 50-54

  Tamiya, Motohiro ^a   Kobayashi, Masashi ^a   Morimura, Osamu ^a   Yasue, Tomomi ^b   Nakasuji, Takashi ^b   Satomu, Morita ^a   Kohei, Okafuji ^a   Takayuki, Shiroyama ^a   Morishita, Naoko ^a   Suzuki, Hidekazu ^a   Sasada, Shinji ^c   Okamoto, Norio ^a   Hirashima, Tomonori ^a   Kawase, Ichiro ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Crosslinked N telopeptide; Lung cancer; NTx; Predictive marker; Type I collagen

Indexed keywords

AMINO TERMINAL TELOPEPTIDE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; GENDER; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLLAGEN TYPE I; CONFIDENCE INTERVALS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PEPTIDES; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84871593000     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.03.012     Document Type: Article

References (29)

1. S.G. Spiro, J.C. Porter Lung cancer - where are we today? Current advances in staging and nonsurgical treatment Am J Respir Crit Care Med 166 2002 1166 1196
2. K.E. Stanley Prognostic factors for survival in patients with inoperable lung cancer J Natl Cancer Inst 65 1980 25 32
3. G.V. Scagliotti, P. Parikh, J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
4. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
5. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
6. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
7. M. Reck, J. von Pawel, P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
8. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
9. L.S. Simon, S.M. Krane, P.D. Wortman Serum levels of type I and III procollagen fragments in Paget's disease of bone J Clin Endocrinol Metab 58 1984 110 120
10. M. Tamiya, H. Suzuki, M. Kobayashi Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer Med Oncol 29 2011 215 218
11. I. Kanakis, M. Nikolaou, D. Pectasides Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer J Pharm Biomed Anal 34 2004 827 832
12. R.E. Coleman Skeletal complications of malignancy Cancer 80 1997 1588 1594
13. L.M. Atley, J.S. Mort, M. Lalumiere Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope Bone 26 2000 241 247
14. F. Lumachi, F. Marino, G. Fanti Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases Preliminary results Anticancer Res 31 2011 3879 3881
15. M. Izumi, Y. Nakanishi, K. Takayama Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma Cancer 91 2001 1487 1493
16. M. Ando, Y. Ando, S. Sugiura Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer Jpn J Cancer Res 90 1999 249 253
17. H. Sugiura, K. Yamada, T. Sugiura Predictors of survival in patients with bone metastasis of lung cancer Clin Orthop Relat Res 466 2008 729 736
18. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
19. E. Vallières, F.A. Shepherd, J. Crowley The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer J Thorac Oncol 4 2009 1049 1059
20. H. Nakamura, K. Ando, T. Shinmyo Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis Ann Thorac Cardiovasc Surg 17 2011 469 480
21. S. Cedrés, I. Nuñez, M. Longo Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC) Clin Lung Cancer 12 2011 172 179
22. J.E. Brown, R.J. Cook, P. Major Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 2005 59 69
23. G. Mountzios, V. Ramfidis, E. Terpos Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data Clin Lung Cancer 12 2011 341 349
24. D. Pectasides, M. Nikolaou, D. Farmakis Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid Anticancer Res 25 2005 1457 1463
25. V. Hirsh, P.P. Major, A. Lipton Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 3 2008 228 236
26. R. Kaira, H. Murakami, K. Kaira N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases Int J Clin Oncol 15 2010 484 488
27. D.H. Henry, L. Costa, F. Goldwasser Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125 1132
28. A. Lipton, L. Costa, S.M. Ali Bone markers in the management of metastatic bone disease Cancer Treat Rev 27 2001 181 185
29. A. Lipton, L. Costa, S. Ali Use of markers of bone turnover for monitoring bone metastases and the response to therapy Semin Oncol 28 2001 54 59